On April 29, 2025, the "Hangzhou Taikun Biopharmaceutical Industry and Finance Summit," jointly organized by Tailong Venture Capital, Tigermed, Hangzhou Industrial Investment Group, and Binjiang Financial Investment Group, was successfully held at the Kaiyuan Mingdu Hotel in Binjiang District, Hangzhou. Jack Wang, Chairman of Hong Kong WinHealth Pharma Group, attended the conference. Meanwhile, WinHealth Pharma also participated as a featured exhibitor.
The summit aimed to promote an in-depth understanding of the biopharmaceutical industry ecosystem and relevant policies in Hangzhou among various sectors, as well as to enhance communication and cooperation among investment institutions. The conference focused on in-depth discussions on cutting-edge technologies in the biopharmaceutical field, industry policies and trends, business development and international expansion, as well as opportunities in AI and industry-finance collaboration. It attracted numerous academicians, experts, industry leaders, top investment banks, and representatives from the Taikun Fund ecosystem to come together.
As a comprehensive, fully-integrated biopharmaceutical company, WinHealth Pharma has always focused on the production, development, and commercialization of innovative drugs, with a commitment to continuously providing more accessible healthcare solutions to patients. At the summit, WinHealth Pharma showcased its core competencies in innovation strategy, global strategic collaboration networks, and product porfolios, attracting many industry professionals to engage in discussions.
This event not only served as a key platform for WinHealth Pharma to demonstrate its brand strength but also marked a critical step in connecting industry resources and exploring collaboration opportunities. Moving forward, the company will continue to strengthen its core competencies, optimize its industry positioning, and collaborate with industry peers to build Hangzhou as a hub for the biopharmaceutical industry, driving the high-quality development of China’s biopharmaceutical sector.
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.